Thermo Fisher Scientific Expands Millersburg, Pa. Bioprocessing Manufacturing Site

$40 million expansion will support increased production of single-use technology for critical vaccines and biologics
Thermo Fisher Scientific is investing $40 million to expand its single-use technology (SUT) manufacturing facility in Millersburg, Pa. The expansion is part of the company’s $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19.
Single-use technologies enable development of a growing number of biological drugs and vaccines, creating unprecedented demand for these products. The Millersburg site expansion will add significant capacity to continue providing the biopharma industry with the technology and materials needed to assist in developing new vaccines, cancer treatments and breakthrough therapies for other conditions.
“Since the start of the pandemic, the Millersburg site has been instrumental in supporting more than 20 pharmaceutical partners developing lifesaving therapies and vaccines,” said Mitch Kennedy, president, single use technologies, Thermo Fisher Scientific. “During the pandemic, our colleagues in Millersburg and around the world answered the call for increased production. Our expanded bioprocessing capabilities will ensure that we can continue to deliver essential supplies to our customers as demand surges.”
Thermo Fisher acquired the Millersburg facility in 2015, and over the last two years has expanded and modernised the warehouse and clean rooms. The second phase of the site expansion includes a new, 47,000-square-foot warehouse and creation of 100 new jobs at various levels. Once fully renovated by mid 2023, Thermo Fisher anticipates that the site will employ more than 1,000 people.
“Pennsylvania is proud that Thermo Fisher Scientific is expanding in Dauphin County and is creating 100 new jobs in the region,” said Governor Tom Wolf. “Pennsylvania is a key destination for groundbreaking businesses with our highly educated, skilled, and talented workforce, leading universities, and location near other major cities. The bioprocessing solutions that Thermo Fisher Scientific will produce in Millersburg will help to power the local economy and strengthen our position in the science and technology sectors.”
“We are tremendously grateful for the vision, investment and job creation Thermo Fisher Scientific is bringing to Millersburg and our hardworking local families,” said U.S. Representative, Scott Perry. “We know our folks will continue to make this world-class company and our community proud.”
Related News
-
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: -
News Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities. -
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance